U.S. markets close in 4 hours 41 minutes
  • S&P 500

    3,267.35
    +20.76 (+0.64%)
     
  • Dow 30

    26,937.31
    +121.87 (+0.45%)
     
  • Nasdaq

    10,801.07
    +128.80 (+1.21%)
     
  • Russell 2000

    1,461.69
    +9.87 (+0.68%)
     
  • Crude Oil

    40.01
    -0.30 (-0.74%)
     
  • Gold

    1,865.90
    -11.00 (-0.59%)
     
  • Silver

    23.02
    -0.18 (-0.76%)
     
  • EUR/USD

    1.1623
    -0.0053 (-0.45%)
     
  • 10-Yr Bond

    0.6560
    -0.0100 (-1.50%)
     
  • GBP/USD

    1.2708
    -0.0044 (-0.35%)
     
  • USD/JPY

    105.6200
    +0.2180 (+0.21%)
     
  • BTC-USD

    10,634.28
    -126.31 (-1.17%)
     
  • CMC Crypto 200

    226.46
    +8.63 (+3.96%)
     
  • FTSE 100

    5,825.28
    +2.50 (+0.04%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

CURE Pharmaceutical to Present at Two Virtual Events in September

Cure Pharmaceutical Holding Corp.

- CURE will present at the LD 500 Virtual Conference, September 4 at 8:20 am PDT - 

- CURE CEO will be a panelist at the 4@4 Forum on September 10 @4pm PDT -

OXNARD, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at two upcoming virtual conferences in September.

  • The LD 500 Virtual Conference on Friday, September 4 at 8:20amPDT/11:20pm EDT
    Rob Davidson, President and CEO of CURE Pharmaceutical will present to a live virtual audience at the LD 500 investor conference on Friday, September 4 at 8:20am PDT. The LD 500 will take place on September 1-4. Register here: https://ld500.ldmicro.com/
    The full conference profile for CURE Pharmaceutical Holdings can be viewed here: https://www.ldmicro.com/profile/CURR.

  • Four At Four Forum on September 10 @ 4pm PDT
    Rob Davidson will be joined by Nancy Duitch, CEO of Sera Labs as featured panelists at the Virtual 4@4 Forum on September 10 at 4pm PDT. The topic for the event is “CBD, Cannabis and the Cannabiz”. Registration is free but is required in advance at: https://4at4cannabiz.eventbrite.com

    CURE announced its intention to acquire Sera Labs on July 28. Sera Labs is a trusted leader in the health, wellness and beauty sectors of CBD and creates high quality products that use science-backed, proprietary formulations and organic hemp. Brand names include: SeraRelief™, SeraTopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™.

About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

CURE’s delivery vehicles include CUREfilm®, an advanced oral thin film; CUREpods™, a novel chewable liquid or solid delivery form; and CUREdrops™, an emulsion technology that can be incorporated into different dosage forms (film, tincture, beverages, etc.), among others.

CURE’s proprietary clinical pipeline includes CUREfilm®Blue (sildenafil to treat erectile dysfunction), and CUREfilm®Canna (THC and CBD). Other OTC wellness products include Vitamin D, BCP Sleep, and Electrolytes. (Visit CURE’s catalog for the complete list.) As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

CONTACT: Investors: Gary Zwetchkenbaum Plum Tree Consulting LLC gzplumtree@gmail.com 516.455.7662 Corporate Communications/Institutional Investors: Ina McGuinness investor@curepharma.com 805.427.1372 Media: Deanne Eagle deanne@planetcommunications.nyc 917.837.5866